Please find this week’s ICARS newsletter attached to this email.

The final stage of the national ceasing audit of the NHS Cervical Screening Programme has commenced and GP practices will be contacted by CSAS if any of your registered patients need to be audited. Please could you respond to CSAS’ request to review your ceased patients records within the timeframe identified by CSAS in their correspondence. The number of patients requiring auditing by a practice will be small.

Thank you for a great start to the 2022/23 flu immunisation season.

Flu - Children
LAIV, the children’s vaccine, has been available to order from 8 September and in line with national messaging we are writing to encourage you to vaccine 2 and 3 year olds, plus clinical at risk children aged 6 months to 18 years as early as possible. The current 2 and 3 year olds experienced limited socialising during the last two flu immunisation seasons due to the pandemic and therefore lack some protection against flu which would have been acquired from being exposed to flu circulating in the community.

As a compliment to your invitation to parents and carers of 2 and 3 year olds, the national call occurred last week, involving a combination of letters, texts and emails being sent out to parents and carers of these children asking them to contact their practice to book their child for
their flu vaccine. Notification of this call was circulated throughout August and September, via both national and regional communications.

**Flu – call for clinical at risk**
There will also be a national call for the clinical at risk. This is to compliment the active call/recall that your practice undertakes for this cohort. Letters are currently being agreed, with the proposed date for the call being early October. We will notify yourselves of the final dates once they become known.

**Flu – Inactivated flu vaccine PGD issue**
It has come to light that the authorised inactivated flu vaccine PGD (version 11.00) excludes clinical at risk 50-64 year olds. If you vaccinate this cohort then a PSD will need to be used until the correct version of the PGD (version 11.00a) is authorised. We will notify you of when the correct version is authorised.

**Flu – Reimbursable vaccines**
A reminder of the reimbursable vaccines for 2022/23 flu immunisation season can be found here:


We are currently unable to comment on reimbursable vaccines for the 2023/24 flu immunisation season as JCVI has not released the information on the recommended flu vaccine types for next year. Once this information is released, NHS England will prepare the reimbursable flu vaccine letter. We will notify you of when both the JCVI and the 2023/24 reimbursable letter are available.

**Flu – healthy 50 to 64 year old cohort become eligible on 15 October 2022**
This cohort becomes eligible on the 15 October, as detailed in the PGD, reimbursement letter and other documents which support the successful delivery of the flu immunisation programme.

The national and regional priority is to vaccinate 2 and 3 year olds and clinical at risk patients first. QIVc, as detailed in the reimbursement letter, is the vaccine to use for your clinical at risk patients.

QIVe vaccine stock was made available to order for the vaccinating of your healthy 50-64 year olds. As detailed in the reimbursement letter, QIVc should only be used if QIVe is not available AND this does not divert QIVc from vaccinating your clinical at risk or over 65 patients.

**Further Information**

- Back issues of these bulletins and attachments are available on the NHSEI website [here](england.nhs.uk).

If you have any questions or wish to provide feedback, please contact the Integrated Public Health Team at [england.swscreeningandimms@nhs.net](mailto:england.swscreeningandimms@nhs.net)